Stockscreener 앱 받기
0.00
100.00%
-8.28
전일 마감가:
$8.28
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$413.12M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
0.00
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Top Cybin (HELP) Competitors 2026 - MarketBeat
Aug PreEarnings: Will Cybin Inc stock recover after earningsDay Trade & Expert Curated Trade Ideas - baoquankhu1.vn
Market Rankings: Can Cybin Inc be the next market leaderWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
symbol__ Stock Quote Price and Forecast - CNN
Aug Update: Can Cybin Inc deliver consistent EPS growthMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cybin (NASDAQ:HELP) Shares Down 2.1%Time to Sell? - MarketBeat
Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th - Psychedelic Alpha
Bank Watch: Can Cybin Inc be the next market leaderWeekly Trade Review & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Ideas: Can Cybin Inc be the next market leader2026 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Cybin Inc.: Fundamental Analysis and Financial Ratings | R7E | CA23256X4075 - marketscreener.com
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Cybin (HELP) Institutional Ownership 2026 $HELP - MarketBeat
Why Is Cybin Inc. (CYBN.NE) Stock Down Today? - Meyka
Investor Mood: What hedge funds are buying Cybin IncQuarterly Investment Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Aug EndMonth: What hedge funds are buying Cybin IncShort Setup & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data - Yahoo Finance
Published on: 2026-03-08 02:13:31 - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP) - The Globe and Mail
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Aug Shorts: Does Cybin Inc stock have upside surprise potential2025 Market Trends & Weekly Top Gainers Alerts - baoquankhu1.vn
Clinical Progress Fails to Lift Cybin's Stock as Regulatory Revisions Weigh - AD HOC NEWS
Analysis Recap: Is Cybin Inc impacted by rising ratesJuly 2025 Gainers & AI Powered Market Entry Strategies - baoquankhu1.vn
Cybin Inc. (CYBN.NE NEO) down 30.12% on 06 Mar 2026: key support ahead - Meyka
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - finance.yahoo.com
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Sahm
Jefferies Maintains Buy on HELP (Cybin Inc. Common Stock) Mar 2026 - Meyka
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety DisorderSlideshow - Seeking Alpha
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Investing News Network
FY2026 Earnings Forecast for Cybin Issued By HC Wainwright - MarketBeat
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
0.51%
자본화:
|
볼륨(24시간):